Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sills, G. J.
Right arrow Articles by Brodie, M.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sills, G. J.
Right arrow Articles by Brodie, M.J.
Related Collections
Right arrow All Epilepsy/Seizures
Neurology 2001;57:196-200
© 2001 American Academy of Neurology
Articles

Visual field constriction

Accumulation of vigabatrin but not tiagabine in the retina G. J. Sills, PhD;, P.N. Patsalos, PhD;, E. Butler, G. Forrest, N. Ratnaraj, PhD and M.J. Brodie, MD

From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Address correspondence and reprint requests to Dr. Graeme J. Sills, Epilepsy Unit, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, Scotland; e-mail: g.j.sills{at}clinmed.gla.ac.uk

BACKGROUND: The antiepileptic drug (AED) vigabatrin (VGB) causes concentric visual field constriction. Anecdotal reports involving tiagabine (TGB) have implied that this may be a class effect of all AEDs with {gamma}-aminobutyric acid (GABA)–related actions. We investigated the pharmacokinetic and pharmacodynamic profiles of VGB and TGB in rat brain and eye.

METHODS: Adult male rats (n = 8) were administered 0.9% saline (control), VGB (500 or 1,000 mg/kg), or TGB (5, 10, or 20 mg/kg). At 1 (TGB) and 4 hours (VGB) postdosing, the animals were killed, a blood sample was obtained, their brains were dissected into five anatomic regions, and the retina and vitreous humor were isolated from each eye. Samples were analyzed for GABA concentrations and the activity of the enzyme GABA-transaminase (GABA-T). Plasma and tissue drug concentrations were also determined.

RESULTS: VGB treatment produced a decrease in the activity of GABA-T and a rise in GABA concentrations in all tissues investigated. This effect was most pronounced in the retina. VGB concentrations were as much as fivefold higher in the retina than in the brain. TGB was without effect on GABA concentrations and activity of GABA-T. TGB concentrations were notably lower in the retina than in the brain.

CONCLUSIONS: Accumulation of VGB in the retina, with or without an increase in GABA, may be responsible for the visual field constriction reported clinically. In contrast, TGB had no effect on GABA concentrations and did not accumulate in the retina. These results suggest that TGB is unlikely to cause visual field defects in humans.




This article has been cited by other articles:


Home page
 IOVSHome page
S. Durbin, G. Mirabella, J. R. Buncic, and C. A. Westall
Reduced Grating Acuity Associated with Retinal Toxicity in Children with Infantile Spasms on Vigabatrin Therapy
Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 4011 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. I. Bekkelund, H. Lilleng, and S. Tonseth
Gabapentin may cause reversible visual field constriction.
BMJ, May 20, 2006; 332(7551): 1193 - 1193.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. McDonagh, L.J. Stephen, F.M. Dolan, S. Parks, G.N. Dutton, K. Kelly, D. Keating, G.J. Sills, and M.J. Brodie
Peripheral retinal dysfunction in patients taking vigabatrin
Neurology, December 23, 2003; 61(12): 1690 - 1694.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G L Krauss, M A Johnson, S Sheth, and N R Miller
A controlled study comparing visual function in patients treated with vigabatrin and tiagabine
J. Neurol. Neurosurg. Psychiatry, March 1, 2003; 74(3): 339 - 343.
[Abstract] [Full Text] [PDF]